ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Clinical Response"

  • Abstract Number: 522 • 2017 ACR/ARHP Annual Meeting

    Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-Label, Long-Term Extension Studies over 9 Years

    Jürgen Wollenhaupt1, Joel Silverfield2, Eun Bong Lee3, Ketti Terry4, Kenneth Kwok5, Sander Strengholt6, Ryan DeMasi7 and Lisy Wang4, 1Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, 2Healthpoint Medical Group, Tampa, FL, 3Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), 4Pfizer Inc, Groton, CT, 5Pfizer Inc, New York, NY, 6Pfizer Inc, Capelle aan den IJssel, Netherlands, 7Pfizer Inc, Collegeville, PA

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here, we report tofacitinib safety and tolerability up to 114…
  • Abstract Number: 885 • 2017 ACR/ARHP Annual Meeting

    48-Week Complete Remission By Ethnic, Sex and Age Subgroups in Patients with Active Lupus Nephritis Treated with Voclosporin

    David Wofsy1, David A. Isenberg2, Frédéric A. Houssiau3, Mary Anne Dooley4, Neil Solomons5 and Simrat Randhawa6, 1Rheumatology, UCSF, San Francisco, CA, 2Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom, 3Rheumatology, Pôle de Maladies Rhumatismales, Université catholique de Louvain, Brussels, Belgium, 4UNC Kidney Centre, Chapel Hill, NC, 5Aurinia Pharmaceuticals Inc., Victoria, BC, Canada, 6Medical Affairs, Aurinia Pharmaceuticals, Victoria, BC, Canada

    Background/Purpose: Voclosporin (VCS) is a novel CNI with a favorable metabolic profile, no observed effect on electrolytes, and a predictable dose response potentially eliminating the…
  • Abstract Number: 1206 • 2017 ACR/ARHP Annual Meeting

    Chondroitin Sulfate Reduces Pain and Improves Function in Knee Osteoarthritis Significantly Better Than Placebo, Independently of the Definition of Responders

    J-Y Reginster, Bone Cartilage Unit, University of Liege, Liege, Belgium

    Background/Purpose: In addition to the assessment of the two co-primary endpoints – pain and function – regulatory agencies recommend the use of responder rates in…
  • Abstract Number: 1477 • 2017 ACR/ARHP Annual Meeting

    Patient-Reported Outcomes As Independent Measures of Treatment Success with Sirukumab, an Anti-IL6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis: Post-Hoc Analysis of 2 Placebo-Controlled Phase 3 Trials

    Vibeke Strand1, Rita Ganguly2, Nan Li3, Prasheen Agarwal3, Shihong Sheng3, Kaiyin Fei3, Kelly McQuarrie3 and Sharon Popik3, 1Division of Immunology/Rheumatology, Stanford University, Stanford, CA, 2GlaxoSmithKline, Collegeville, PA, 3Janssen Research & Development, LLC, Spring House, PA

    Background/Purpose: Sirukumab, a selective, high-affinity, human anti–IL-6 monoclonal antibody, is in development for rheumatoid arthritis (RA) and other diseases.  Effects of sirukumab on RA symptoms…
  • Abstract Number: 1518 • 2017 ACR/ARHP Annual Meeting

    Certolizumab Pegol Effectiveness and Retention Rate in Psoriatic Arthritis. Real Life Data

    Arantxa Conesa1, Manuel Fernández2, Rosa Expósito3, Jose Campos4, Jose Ramon Lamua5, Maria del Pilar Navarro6, Paula Rubio-Muñoz7, Pilar Ahijado-Guzman8 and Carlos M Gonzalez9, 1Hospital Clínico Universitario de Valencia, Valencia, Spain, 2Hospital Universitario de Guadalajara, Guadalajara, Spain, 3Rheumatology, Hospital Comarcal de Laredo. Spain, Laredo, Spain, 4Rheumatology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, 5Hospital del Henares, Madrid, Spain, 6Hospital de Fuenlabrada, Fuenlabrada, Spain, 7Rheumatology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 8Rheumatology Unit. Fuenlabrada’s Hospital, Madrid, Madrid, Spain, 9Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain

    Background/Purpose: To evaluate the effectiveness and safety of Certolizumab Pegol (CZP) in a real word setting in Psoriatic Arthritis (PsA) patients. Methods: Multicentric cohort of…
  • Abstract Number: 1838 • 2017 ACR/ARHP Annual Meeting

    Estimating Duration of Response in Systemic Lupus Erythematosus (SLE) Trials

    Mimi Kim1, Joan T. Merrill2, Kenneth C. Kalunian3, Leslie Hanrahan4 and Peter M. Izmirly5, 1Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, 2Oklahoma Medical Research Foundation, Oklahoma City, OK, 3Division of Rheumatology, Allergy and Immunology, UCSD School of Medicine, La Jolla, CA, 4Lupus Foundation of America, Washington DC, DC, 5Rheumatology, New York University School of Medicine, New York, NY

    Background/Purpose: The primary endpoint in SLE trials is usually response to therapy at a landmark visit. However, during a trial, patients may alternate between response…
  • Abstract Number: 2371 • 2017 ACR/ARHP Annual Meeting

    The Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis Stratified By Baseline Body Mass Index

    Ara Dikranian1, Miguel Angel Gonzalez-Gay2, Frank Wellborne3, Jose Maria Alvaro-Gracia4, Liza Takiya5, Lori Stockert5, Douglass Chapman6, Svitlana Tatulych7, Palle Dahl8 and Jeffrey R. Curtis9, 1Cabrillo Center for Rheumatic Disease, San Diego, CA, 2Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 3Houston Institute for Clinical Research, Houston, TX, 4Hospital Universitario de La Princesa, IIS Princesa, Madrid, Spain, 5Pfizer Inc, Collegeville, PA, 6Pfizer Inc, New York, NY, 7Pfizer Inc, Groton, CT, 8Pfizer Inc, Ballerup, Denmark, 9University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). This post-hoc analysis aims to explore the efficacy of tofacitinib…
  • Abstract Number: 2454 • 2017 ACR/ARHP Annual Meeting

    Real-World Consistency of Response to Adalimumab over Time in Patients with Rheumatoid Arthritis: Results from the Corrona Registry

    Dimitrios A. Pappas1,2, George W. Reed2,3, Chitra Karki4, Jenny Griffith5, Martha Skup5, Vishvas Garg5 and Joel Kremer2,6, 1Columbia University, New York, NY, 2Corrona LLC, Southborough, MA, 3UMass Medical School, Worcester, MA, 4Corrona, LLC, Southborough, MA, 5AbbVie Inc., North Chicago, IL, 6Albany Medical College and The Center for Rheumatology, Albany, NY

    Background/Purpose: Adalimumab (ADA) was approved in the US in 2002 for rheumatoid arthritis (RA), and subsequently approved for the management of other inflammatory diseases such…
  • Abstract Number: 84 • 2017 Pediatric Rheumatology Symposium

    Predictors of Corticosteroid Discontinuation, Complete Clinical Response and Remission in Patients with Juvenile Dermatomyositis

    Takayuki Kishi1, William Warren-Hicks2, Michael Ward3, Nastaran Bayat1, Lan Wu1, Gulnara Mamyrova4, Ira N. Targoff5, Frederick Miller1, Lisa G. Rider1 and the Childhood Myositis Heterogeneity Study Group, 1Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institute of Health, Bethesda, MD, 2EcoStat, Inc., Mebane, NC, 3National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 4Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, 5VA Medical Center, University of Oklahoma Health Sciences Center, and Oklahoma Medical Research Foundation, Oklahoma City, OK

    Background/Purpose:  Factors affecting treatment (Rx) responses in juvenile dermatomyositis (JDM) are not well understood.  We examined a large JDM registry for predictors of excellent Rx…
  • Abstract Number: 19L • 2016 ACR/ARHP Annual Meeting

    Biosimilar Infliximab (CT-P13) Is Not Inferior to Originator Infliximab: Results from a 52-Week Randomized Switch Trial in Norway

    Guro Løvik Goll1,2, Inge C Olsen3, Kristin K Jorgensen4, Merete Lorentzen5, Nils Bolstad6, Espen A. Haavardsholm7, Knut EA Lundin8, Cato Mork9, Jorgen Jahnsen4, Tore K Kvien3 and the NOR-SWITCH study group, 1Dept of Rheumatoogy, Diakonhjemmet Hospital, Oslo, Norway, 2Department of Rheumathology, Diakonhjemmet Hospital, Oslo, Norway, 3Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 4Dept of Gastroenterology, Akershus University Hospital, Lorenskog, Norway, 5Dept of Dermatology, Rikshospitalet, Oslo, Norway, 6Department of Medical Biochemistry,, OUS-Radiumhospitalet, Oslo, Norway, 7Diakonhjemmet Hospital, Oslo, Norway, 8Dept of gastroenterology, Rikshospitalet, Oslo, Norway, 9Dept of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway

      Background/Purpose: TNF-inhibitors (TNFi) have improved treatment of  spondyloarthritis (SpA), rheumatoid arthritis (RA), psoriatic arthritis (PsA),  Crohn’s disease (CD), ulcerative colitis (UC), and chronic plaque…
  • Abstract Number: 2920 • 2016 ACR/ARHP Annual Meeting

    The Effect of Rituximab on B Cells in Skin and Peripheral Blood in Systemic Sclerosis

    Maaike Boonstra1, Annemarie L. Dorjée1, Koen D. Quint2, Tom W.J. Huizinga1, Hans U. Scherer3 and Jeska K. de Vries-Bouwstra1, 1Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Dermatology, Leiden University Medical Center, Leiden, Netherlands, 3Rheumatology, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Open-label studies provided evidence for possible efficacy of rituximab (RTX) in systemic sclerosis (SSc). Previously, we reported on a randomized placebo-controlled clinical trial in…
  • Abstract Number: 300 • 2016 ACR/ARHP Annual Meeting

    Mindfulness Predicts Treatment Response from Non-Pharmacological Therapy in Knee Osteoarthritis

    Augustine Lee1, Lori Lyn Price2, Xingyi Han3, Mei Chung4, William F. Harvey1, Jeffrey Driban5, Timothy E. McAlindon6 and Chenchen Wang1, 1Rheumatology, Tufts Medical Center, Boston, MA, 2Clinical Care Research, Tufts Medical Center, Boston, MA, 3Public Health and Community Medicine, Tufts University, Boston, MA, 4Department of Public Health and Community Medicine, Tufts University School of Medicine, Boston, MA, 5Tufts Medical Center, Boston, MA, 6Division of Rheumatology, Tufts Medical Center, Boston, MA

    Background/Purpose: Mindfulness is the ability to maintain a heightened awareness of one's moment-to-moment experiences without judging or reacting. Recent evidence suggests that mindfulness may improve…
  • Abstract Number: 3153 • 2016 ACR/ARHP Annual Meeting

    Automated Cell Phone Monitoring of Disease Activity and Medication Adherence in Early Rheumatoid Arthritis

    Laura Kuusalo1,2, Hannu Kautiainen3, Tuulikki Sokka-Isler4, Toini Uutela5, Laura Pirilä2, Timo Yli-Kerttula6, Markku J Kauppi7,8, Tuomas Rannio9, Kirsi Paalanen10, Arto Kokko9, Juha Asikainen9, Jelena Borodina10, Johanna Paltta2, Kari Laiho11, Andrus Mullanmaa12, Kari Puolakka12 and SandRA Study Group, 1University of Turku, Turku, Finland, 2Turku University Hospital, Turku, Finland, 3Unit of Primary Health Care, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, 4Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland, 5Lapland Central Hospital, Rovaniemi, Finland, 6Sairaalantie 3, Satakunta Central Hospital, Rauma, Finland, 7School of Medicine, University of Tampere, Tampere, Finland, 8Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland, 9Jyvaskyla Central Hospital, Jyväskylä, Finland, 10Jyvaskyla Central Hospital, Jyvaskyla, Finland, 11Päijät-Häme Central Hospital, Lahti, Finland, 12South Karelia Central Hospital, Lappeenranta, Finland

    Background/Purpose: Remission targeted treatment of early RA requires frequent monitoring. However, in clinical practice monitoring frequency is not always optimal due to factors like limited…
  • Abstract Number: 607 • 2016 ACR/ARHP Annual Meeting

    The Clinical Response to Biologic and Non-Biologic Disease Modifying Antirheumatic Drugs (DMARDs) According to Gender in a French-Canadian Population with Rheumatoid Arthritis (RA)

    Sonia Lagacé1, Louis Bessette2,3, Louis Coupal4 and Denis Choquette4, 1Medicine, Laval University, Quebec, QC, Canada, 2Rheumatology, Laval University, Québec, QC, Canada, 3Rhumatologie, CHU de Québec - Université Laval, Quebec, QC, Canada, 4Rheumatology, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montréal, QC, Canada

    Background/Purpose: Several studies have reported that women with RA had higher level of pain, disease activity and functional impairment compared to men. In addition, women…
  • Abstract Number: 745 • 2016 ACR/ARHP Annual Meeting

    Clinical and Laboratory Correlates of Response in a Phase 3 Clinical Trial of Belimumab or Placebo Administered Subcutaneously Plus Standard Care to Patients with Systemic Lupus Erythematosus (SLE)

    Ronald F. van Vollenhoven1, William Stohl2, Richard Furie3, Norma Lynn Fox4, James Groark5, Damon Bass5, Milena Kurtinecz5, Bonnie Pobiner6, William Eastman6, Tania Gonzalez-Rivera5 and David Gordon5, 1Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands, 2Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, 3Division of Rheumatology, Northwell Health, Great Neck, NY, 4GSK, Potomac, MD, 5GSK, Philadelphia, PA, 6GSK, Research Triangle Park, NC

    Background/Purpose: The SRI (SLE responder index) is a composite measure established as a primary endpoint in SLE clinical trials. However, it has been questioned whether…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 7
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology